Dialing in Gene Therapy.

How it works

The goal of gene therapy for underlying genetic diseases such as muscular dystrophy or hemophilia is long-term gene expression. Yet there are gene therapy applications in which only short-term expression of a transgene is desirable, such as in the treatment of time-limited diseases such as autoimmunity, infection, or cancer. Another application would be a circumstance in which the gene therapy might cause unwanted side effects, and there would be a desire to inactivate the transgene such as CRISPR/Cas9. Current methods do not allow for controlled expression of trans gene in human patients.

TransSkip is a novel method for controlling transgene expression in gene therapy applications. TransSkip technology enables transgene expression to be dependent on administration of drug. Following a single dose of the viral vector, administration of the drug activates gene expression, and upon discontinuation of the drug expression reverts to being inactive.

partner with us
Believe in our vision? 
Contact us to see how we can work together
get more info